Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.58 |
| ▸ | HNF4A | P41235 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.51 |
| ▸ | ABAT | P80404 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69585 | 0.91 | SNCA (0.62) | SNCAPOLBALDH1A1MAPK1TP53 | |
| SCHEMBL30477507 | 0.91 | SNCA (0.62) | SNCAPOLBALDH1A1MAPK1TP53 | |
| SCHEMBL27986576 | 0.84 | HTR1A (0.50) | IDH1HNF4ASNCAPOLBALDH1A1 | |
| SCHEMBL11002820 | 0.80 | MAPK1 (0.60) | SNCAPOLBALDH1A1MAPK1TP53 | |
| SCHEMBL1601620 | 0.80 | ALDH1A1 (0.53) | POLBALDH1A1MAPK1TSHRSMN1; SMN2 | |
| SCHEMBL9511525 | 0.80 | VCAM1 (0.56) | POLBALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL10652958 | 0.80 | CES2 (0.53) | POLBALDH1A1MAPK1HPGDTSHR | |
| SCHEMBL29936572 | 0.80 | VCAM1 (0.56) | POLBALDH1A1MAPK1HPGDSMN1; SMN2 | |
| SCHEMBL1736272 | 0.79 | POLB (0.62) | SNCAPOLBALDH1A1MAPK1TP53 | |
| SCHEMBL7219341 | 0.79 | HSPB1 (0.49) | POLBALDH1A1MAPK1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104788398-B | Benzoxazoles class compound and its production and use | 上海交通大学 | 2017-09-08 | — | — | CN | disclosed |
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-0869949-B1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO MCNEIL PHARM INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-5854242-A | Benzoxazine antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0869949-A1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5696117-A | BACTERICIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997017333-A1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5516911-A | Fluorescent intracellular calcium indicators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | IDH1 3910/4885HNF4A 3052/4885SNCA 3832/4885 |
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDH1 198/4885HNF4A 4049/4885SNCA 2967/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | IDH1 3910/4885HNF4A 3052/4885SNCA 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.